Division of Hematology and Medical Oncology, James Graham Brown Cancer Center, University of Louisville School of Medicine, Louisville, KY, USA.
Division of Medical Oncology, Sylvester Comprehensive Cancer Center, Miami, FL, USA.
Semin Oncol. 2018 Aug;45(4):226-231. doi: 10.1053/j.seminoncol.2018.09.001. Epub 2018 Nov 13.
Advanced age is a risk factor for cancer and is attributed to dysregulation of the immune system. Historically, treatment of advanced cancer has primarily involved systemic chemotherapy that is associated with high treatment related toxicity especially in older adults. Immune checkpoint inhibitors (ICIs) provide an exciting treatment option for older adults in terms of efficacy and safety as compared to systemic chemotherapy. Given the pace of approval of ICIs for multiple cancers, there is an increase in both the use of ICIs and the associated immune-related adverse events. In this article, we address how to approach immunotherapy related toxicities in older adults given the availability of limited data.
高龄是癌症的一个危险因素，这归因于免疫系统的失调。从历史上看，晚期癌症的治疗主要涉及全身性化疗，这与老年人的高治疗相关毒性有关。与全身化疗相比，免疫检查点抑制剂 (ICIs) 在疗效和安全性方面为老年人提供了令人兴奋的治疗选择。鉴于批准用于多种癌症的 ICI 的步伐加快，ICI 的使用及其相关的免疫相关不良事件都在增加。在本文中，鉴于有限的数据，我们将讨论如何在老年人中处理与免疫疗法相关的毒性。
